Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AbbVie Inc | London | Healthcare | Pharmaceuticals | £259.64B | 94.2x | -3.67 | GBX 17,104.79 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding | London | Healthcare | Pharmaceuticals | £194.35B | 21.8x | -1.98 | GBX 23,711.69 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding Participation | London | Healthcare | Pharmaceuticals | £194.35B | 21.8x | -1.98 | GBX 22,483.96 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | London | Healthcare | Pharmaceuticals | £171.91B | 27.9x | 0.96 | GBX 11,086 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24% Upside | Upgrade to Pro+ | |
Novartis | London | Healthcare | Pharmaceuticals | £171.18B | 17.2x | -1.34 | GBX 8,824.08 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk L | London | Healthcare | Pharmaceuticals | £164.62B | 12.9x | 0.53 | GBX 3,670.54 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck & Co Inc | London | Healthcare | Pharmaceuticals | £148.27B | 12.3x | 0.6 | GBX 5,928.80 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | London | Healthcare | Pharmaceuticals | £110.28B | 23.6x | 0.05 | GBX 8,951.52 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi L | London | Healthcare | Pharmaceuticals | £86.13B | 15.9x | 0.13 | GBX 7,055.41 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc | London | Healthcare | Pharmaceuticals | £56.34B | 16.7x | -1.06 | GBX 1,404.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.4% Upside | Upgrade to Pro+ | |
Merck KGaA | London | Healthcare | Pharmaceuticals | £41.76B | 16.4x | 1.77 | GBX 9,578.90 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
HALEON | London | Healthcare | Pharmaceuticals | £31.86B | 21.5x | 0.5 | GBX 355 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.3% Upside | Upgrade to Pro+ | |
UCB L | London | Healthcare | Pharmaceuticals | £30.74B | 26.7x | 0.06 | GBX 16,141.69 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bayer L | London | Healthcare | Pharmaceuticals | £22.06B | -7.5x | 0.04 | GBX 2,233.61 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sandoz | London | Healthcare | Pharmaceuticals | £18.57B | 112.1x | GBX 4,374.02 | 67.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Biogen | London | Healthcare | Pharmaceuticals | £13.99B | 12.3x | 0.4 | GBX 9,642.45 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Recordati Industria | London | Healthcare | Pharmaceuticals | £8.97B | 25.5x | 4.89 | GBX 4,326.59 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Orion Oyj | London | Healthcare | Pharmaceuticals | £8.09B | 24.8x | 0.39 | GBX 5,737.16 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ipsen L | London | Healthcare | Pharmaceuticals | £7.61B | 19.7x | -0.57 | GBX 9,250.18 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Swedish Orphan Biovitrum publ | London | Healthcare | Pharmaceuticals | £7.36B | 21.6x | 0.22 | GBX 2,127.10 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Grifols Pref | London | Healthcare | Pharmaceuticals | £6.58B | 28.6x | 0.19 | GBX 782.50 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Grifols | London | Healthcare | Pharmaceuticals | £6.58B | 28.6x | 0.19 | GBX 1,078.41 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ALK-ABELLO | London | Healthcare | Pharmaceuticals | £4.70B | 43.4x | 0.65 | GBX 1,730.59 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Richter Gedeon Vegyeszeti Gyar | London | Healthcare | Pharmaceuticals | £4.18B | 8.6x | -1.23 | GBX 1,103.82 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hikma Pharma | London | Healthcare | Pharmaceuticals | £3.95B | 14.3x | 0.45 | GBX 1,785 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 43.6% Upside | Upgrade to Pro+ | |
H Lundbeck L | London | Healthcare | Pharmaceuticals | £3.92B | 11.6x | 0.28 | GBX 407.14 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dottikon Es Holding | London | Healthcare | Pharmaceuticals | £3.79B | 39.1x | 1.25 | GBX 27,257.44 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Camurus | London | Healthcare | Pharmaceuticals | £2.93B | 52x | 0.25 | GBX 4,897.73 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Virbac SA | London | Healthcare | Pharmaceuticals | £2.38B | 18.9x | 0.91 | GBX 28,254.43 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Almirall | London | Healthcare | Pharmaceuticals | £1.92B | 102.9x | 0.65 | GBX 893.79 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hutchison China | London | Healthcare | Pharmaceuticals | £1.92B | 5.5x | 0 | GBX 223 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Fagron NV | London | Healthcare | Pharmaceuticals | £1.31B | 17.7x | 1.85 | GBX 1,807.42 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pharma Mar | London | Healthcare | Pharmaceuticals | £1.20B | 53.3x | GBX 6,831.10 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Faes Farma | London | Healthcare | Pharmaceuticals | £1.12B | 12.4x | 1.55 | GBX 364.07 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Uniphar | London | Healthcare | Pharmaceuticals | £883.12M | 11x | 0.37 | GBX 339 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.6% Upside | Upgrade to Pro+ | |
Cosmo Pharmas | London | Healthcare | Pharmaceuticals | £815.78M | 16x | GBX 5,057.52 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Biogaia AB | London | Healthcare | Pharmaceuticals | £735M | 33x | -1.15 | GBX 734.84 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Medincell | London | Healthcare | Pharmaceuticals | £454.08M | GBX 1,362.25 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Allergy Therapeutics | London | Healthcare | Pharmaceuticals | £393.23M | -10.9x | -0.15 | GBX 8.25 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Beximco Pharma. | London | Healthcare | Pharmaceuticals | £300.06M | 7.9x | 0.28 | GBX 47.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Niox PLC | London | Healthcare | Pharmaceuticals | £294.12M | 87.9x | -1.32 | GBX 70.40 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.4% Upside | Upgrade to Pro+ | |
Animalcare | London | Healthcare | Pharmaceuticals | £182.13M | 34x | 0.03 | GBX 264 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.2% Upside | Upgrade to Pro+ | |
Santhera Pharmas Holding | London | Healthcare | Pharmaceuticals | £153.05M | -3.5x | 0.02 | GBX 1,174.59 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Photocure | London | Healthcare | Pharmaceuticals | £118.53M | -309.4x | 2.17 | GBX 441.84 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Venture Life Group | London | Healthcare | Pharmaceuticals | £77.15M | -3,100x | 21.64 | GBX 60.25 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eco Animal | London | Healthcare | Pharmaceuticals | £49.68M | 29.5x | 0.49 | GBX 74 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Shield Therapeutics | London | Healthcare | Pharmaceuticals | £48.65M | -1.8x | -0.09 | GBX 4.60 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CRUSHMETRIC | Aquis Exchange | Healthcare | Pharmaceuticals | £30.51M | -4.5x | GBX 12.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Probiotix | Aquis Exchange | Healthcare | Pharmaceuticals | £14.23M | -13x | GBX 9 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Oasmia Pharma | London | Healthcare | Pharmaceuticals | £10.07M | -3.3x | -0.05 | GBX 1.79 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |